How late after completion of adjuvant capecitabine and radiation would you consider adjuvant olaparib for a patient with gBRCA mutated TNBC?  

Given that olaparib was given within 12 weeks of completion of standard adjuvant therapy on the trial, will you still offer it to patients outside that window now that the data has been released? Would 1 year later be acceptable?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Loyola University Chicago Stritch School of Medicine
See also this Q&A from UCLA tumor board regard...
Sign in or Register to read more